The components have their own evidence, but there is no established human evidence proving that this exact blend works as a combination. Direct combination evidence is shown separately when it exists.
Still uncertain: Whether the combination works better together, optimal ratio, human benefit, long-term safety or a validated human regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Two-peptide GH-axis blend
Entity type
Peptide blend
Research focus
Growth-hormone axis research
Human evidence
Separate human pharmacology exists for related CJC/GHRH compounds and ipamorelin, but no controlled human trial establishing efficacy or safety of the named co-administration blend was identified.
Regulatory status
No approved medicine corresponding to this combination was identified.
Main limitations
Combination synergy, optimal ratio, clinical efficacy, long-term safety or a validated human regimen.
Safety
Endocrine effects, unknown interaction/tolerability at commercial formulations, and identity/purity uncertainty.
Evidence reviewed
2026-09-18
i
Separate human pharmacology exists for related CJC/GHRH compounds and ipamorelin, but no controlled human trial establishing efficacy or safety of the named co-administration blend was identified.
Outcome-level evidence
Evidence is not one score.
This section separates the evidence status from what the evidence actually found. Direct combination evidence is never inferred from component studies.
Does the named CJC-without-DAC + ipamorelin blend have direct controlled human combination evidence?
Evidence gap
Documented evidence gap — component evidence only
Search conclusion: No direct controlled human combination efficacy/safety trial identified in the project research passes.
Public wording rule: Describe Modified-GRF/CJC-related and ipamorelin evidence separately; state that combination synergy, optimal ratio and long-term safety are unestablished.
Evidence rule: absence of direct combination evidence is a research conclusion when the search has been documented; it is not permission to infer efficacy from the components.
Evidence synthesis
✓No direct controlled human efficacy or safety trial of the named CJC-without-DAC + ipamorelin blend was identified.
Important limitations
!Combination synergy, optimal ratio and long-term safety remain unestablished.
!Human pharmacology for related CJC/GHRH compounds and ipamorelin separately cannot establish efficacy or safety of the named blend.
Selected study & evidence records
No structured study detail is currently rendered for this page.
Safety and unknowns
Endocrine effects, unknown interaction/tolerability at commercial formulations, and identity/purity uncertainty.
Technical details
Mechanism / biologyCombines a short-acting GHRH analogue with a ghrelin-receptor/GH-secretagogue agonist to stimulate GH through complementary pathways.
Route / formulation boundaryComponent studies do not establish the efficacy or safety of the blend.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No clinical regimen for the exact CJC-without-DAC + ipamorelin blend identified; ipamorelin data alone do not establish the blend dose or ratio.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
0structured study records
0outcome records
4linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
